Please use this identifier to cite or link to this item: https://scholarbank.nus.edu.sg/handle/10635/118708
Title: HIGHLY EFFICIENT RUNX1 ENHANCER (ER1)- MEDIATED GENETIC ENGINEERING FOR HEMATOPOIETIC STEM CELLS
Authors: KOH CAI PING
Keywords: Hematopoietic stem cells, eR1-CreERT2 Tg mouse
Issue Date: 21-Aug-2014
Citation: KOH CAI PING (2014-08-21). HIGHLY EFFICIENT RUNX1 ENHANCER (ER1)- MEDIATED GENETIC ENGINEERING FOR HEMATOPOIETIC STEM CELLS. ScholarBank@NUS Repository.
Abstract: THERE HAS BEEN CONSIDERABLE INTEREST IN IDENTIFYING CIS-REGULATORY ELEMENTS THAT TARGET GENE EXPRESSION TO STEM CELLS. THESE ELEMENTS COULD SERVE AS MOLECULAR HANDLES FOR STEM CELL-SPECIFIC GENETIC ENGINEERING TOOLS, THEREBY BECOMING INVALUABLE TO STEM CELL RESEARCH. HERE, WE SHOW THE SUCCESSFUL GENERATION OF A TAMOXIFEN (TM)-INDUCIBLE TRANSGENIC (TG) MOUSE MODEL EMPLOYING PREVIOUSLY IDENTIFIED HSC-SPECIFIC RUNX1 ENHANCER, ER1 (+24M). THE KINETICS ANALYSIS AFTER TM INJECTION AND BONE MARROW TRANSPLANTATION ASSAYS CLEARLY REVEALED THAT ER1-DRIVEN CREERT2 ACTIVITY WAS LIMITED TO A SUBSET OF LONG TERM-HSCS (LT-HSCS) IN THE CD34-FLT3-C-KIT+SCA1+LINEAGE- FRACTION. THE ACTIVATION OF ONCOGENIC KRAS INITIATED HEMATOPOIETIC MALIGNANCIES IN THE TM-INJECTED ER1-CREERT2 TG; KRAS-LSL-G12D MICE, WHEREAS NEVER IN NON-TM INJECTED MICE. FURTHERMORE, ER1 IS HIGHLY ACTIVE IN LEUKEMIA STEM CELLS (LSCS). TRANSPLANTATION OF ER1-DRIVEN EGFPHIGH, BUT NOT EGFP-/EGFPLOW, CELLS WITH ONCOGENIC KRAS MUTANT WERE CA
URI: http://scholarbank.nus.edu.sg/handle/10635/118708
Appears in Collections:Ph.D Theses (Open)

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
01 Title page.pdf13.18 kBAdobe PDF

OPEN

NoneView/Download
02 Thesis Front pages.pdf295.48 kBAdobe PDF

OPEN

NoneView/Download
03 PhD Thesis Final (Koh Cai Ping).pdf4.27 MBAdobe PDF

OPEN

NoneView/Download

Page view(s)

211
checked on Oct 14, 2021

Download(s)

140
checked on Oct 14, 2021

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.